HeXun Biosciences CoROCO:6986 23 Gross Margin % is 90.30% as of Dec. 2025, which is 0% below its 10-year median of 90.50. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 732 Biotechnology companies, HeXun Biosciences Co ranks better than 82.24% on this metric.
The historical rank and industry rank for HeXun Biosciences Co's Gross Margin % or its related term are showing as below:
ROCO:6986'
s Gross Margin % Range Over the Past 10 Years
Min: 87.1 Med: 90.5 Max: 91.01
Current: 88.62
During the past 6 years, the highestGross Margin % of HeXun Biosciences Co was 91.01%. The lowest was 87.10%. And the median was 90.50%.
ROCO:6986's Gross Margin % is ranked better than 82.24% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:6986: 88.62
HeXun Biosciences Co had a gross margin of 90.30% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for HeXun Biosciences Co was 0.00% per year.
HeXun Biosciences Co (ROCO:6986) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
HeXun Biosciences Co had a gross margin of 90.30% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
HeXun Biosciences Co Gross Margin % Related Terms
HeXun Biosciences Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
HeXun Biosciences Co (ROCO:6986) has a Gross Margin % of 90.30% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on HeXun Biosciences Co and its competitors. This is near median its historical median of 90.50. Over the past decade, HeXun Biosciences Co's Gross Margin % has ranged from 87.10 to 91.01. According to the industry distribution chart, HeXun Biosciences Co ranks #130 out of 732 companies in the Biotechnology industry, placing it in the top 17.8%.
Is HeXun Biosciences Co's Gross Margin % too high?
HeXun Biosciences Co's current Gross Margin % of 90.30% is near median its 10-year median of 90.50. Over the past 10 years, this metric has ranged from a low of 87.10 to a high of 91.01. The Biotechnology industry median Gross Margin % is 60.91. HeXun Biosciences Co's value of 90.30% is 48.3% above this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #130 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #130 out of 732 companies for Gross Margin %. This places HeXun Biosciences Co in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. HeXun Biosciences Co's value of 90.30% is 48.3% above this benchmark. Historically, HeXun Biosciences Co's own Gross Margin % has ranged from 87.10 to 91.01 over the past decade. While the company's 10-year median is 90.50 vs. the industry median of 60.91, HeXun Biosciences Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current Gross Margin % of 90.30% is 48.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on HeXun Biosciences Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current Gross Margin % is 90.30%, which is near median its own 10-year median of 90.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Gross Margin % of 90.30%. The current Gross Margin % is 90.30%, which is near median its 10-year median of 90.50 and 48.3% above the Biotechnology industry median of 60.91. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Gross Margin % is 90.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
